Page last updated: 2024-09-02

fingolimod hydrochloride and Leukopenia

fingolimod hydrochloride has been researched along with Leukopenia in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baharnoori, M; Chitnis, T; Chua, A; Diaz-Cruz, C; Gonzalez, CT; Healy, BC; Stankiewicz, J; Weiner, HL	1
Arnold, DL; Banwell, B; Bar-Or, A; Brück, W; Chen, Y; Chitnis, T; Gärtner, J; Ghezzi, A; Giovannoni, G; Greenberg, B; Krupp, L; Merschhemke, M; Putzki, N; Rostásy, K; Stites, T; Tardieu, M; Waubant, E; Wolinsky, JS	1
Ando, Y; Ikeda, T; Kakuma, T; Watari, M	1

Trials

1 trial(s) available for fingolimod hydrochloride and Leukopenia

Article	Year
Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. The New England journal of medicine, 2018, 09-13, Volume: 379, Issue:11 Topics: Administration, Oral; Adolescent; Brain; Child; Female; Fingolimod Hydrochloride; Headache; Humans; Immunologic Factors; Infections; Injections, Intramuscular; Interferon-beta; Leukopenia; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Secondary Prevention	2018

Article

Year

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.

The New England journal of medicine, 2018, 09-13, Volume: 379, Issue:11

Topics: Administration, Oral; Adolescent; Brain; Child; Female; Fingolimod Hydrochloride; Headache; Humans; Immunologic Factors; Infections; Injections, Intramuscular; Interferon-beta; Leukopenia; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Secondary Prevention

2018

Other Studies

2 other study(ies) available for fingolimod hydrochloride and Leukopenia

Article	Year
Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count. Multiple sclerosis and related disorders, 2018, Volume: 20 Topics: Adult; Dimethyl Fumarate; Drug Substitution; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Leukocyte Count; Leukopenia; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Multiple Sclerosis; Prognosis; Prospective Studies; Retrospective Studies	2018
Fingolimod-induced decrease in heart rate may predict subsequent decreasing degree of lymphocytes. Scientific reports, 2018, 11-06, Volume: 8, Issue:1 Topics: Adult; Case-Control Studies; Cells, Cultured; Female; Fingolimod Hydrochloride; Heart Rate; Humans; Immunosuppressive Agents; Leukopenia; Lymphocytes; Male; Multiple Sclerosis	2018

Article

Year

Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.

Multiple sclerosis and related disorders, 2018, Volume: 20

Topics: Adult; Dimethyl Fumarate; Drug Substitution; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Leukocyte Count; Leukopenia; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Multiple Sclerosis; Prognosis; Prospective Studies; Retrospective Studies

2018

Fingolimod-induced decrease in heart rate may predict subsequent decreasing degree of lymphocytes.

Scientific reports, 2018, 11-06, Volume: 8, Issue:1

Topics: Adult; Case-Control Studies; Cells, Cultured; Female; Fingolimod Hydrochloride; Heart Rate; Humans; Immunosuppressive Agents; Leukopenia; Lymphocytes; Male; Multiple Sclerosis

2018